Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children
Sponsor: Rafael Correa-Rocha
Summary
The investigators developed a protocol to isolate Treg cells from thymic tissue (thyTreg) discarded in pediatric cardiac surgeries. After completing the pre-clinical studies, the investigators have initiated a phase I/II clinical trial to test the safety and efficacy of the adoptive transfer of autologous thyTreg to prevent rejection in heart transplant children. Condition or disease: Heart Transplantation Intervention/treatment: Regulatory T Cell (Treg) Infusion
Official title: Randomized, Exploratory and Prospective Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of the Transfusion of Autologous Treg Cells Obtained From Thymic Tissue in the Prevention of Rejection in Heart Transplant Children
Key Details
Gender
All
Age Range
Any - 2 Years
Study Type
INTERVENTIONAL
Enrollment
11
Start Date
2020-09-10
Completion Date
2026-12-31
Last Updated
2025-02-03
Healthy Volunteers
No
Conditions
Interventions
Autologous thyTreg
Treg lymphocytic cells, differentiated, autologous, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
Locations (1)
Hospital General Universitario Gregorio Marañon
Madrid, Madrid, Spain